Longitudinal changes in epigenetic age acceleration in aviremic HIV-infected recipients of long-term antiretroviral treatment
The Journal of Infectious Diseases — Esteban-Cantos A, Montejano R, Rodríguez-Centeno J, et al. | June 25, 2021
The present study was conducted to explore longitudinal changes in epigenetic age acceleration in aviremic HIV-infected recipients of long-term antiretroviral treatment. In this study, 63 long-term aviremic HIV-infected adults were longitudinally analyzed. Researchers estimated epigenetic age acceleration (EAA) measures based on three epigenetic clocks using blood DNA methylation patterns (Horvath´s clock, PhenoAge and GrimAge). The emergence of serious AIDS-related and non-AIDS-related events were recorded to evaluate its relationship with EAA. The data showed that after four years of successful antiretroviral treatment, epigenetic aging did not accelerate in long-term aviremic HIV-infected adults. It has been concluded that EAA measures deserve future research as potential tools for predicting clinical events.